Fresenius Medical Care AG & Co KGaA
XETRA:FME
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.13
42.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fresenius Medical Care AG & Co KGaA
Cash & Cash Equivalents
Fresenius Medical Care AG & Co KGaA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Cash & Cash Equivalents
€1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Cash & Cash Equivalents
€1.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
Vita 34 AG
XETRA:V3V
|
Cash & Cash Equivalents
€14.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
16%
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Cash & Cash Equivalents
HK$720.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Synlab AG
XETRA:SYAB
|
Cash & Cash Equivalents
€220.9m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Cash & Cash Equivalents
€1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
Fresenius Medical Care AG & Co KGaA
Glance View
Fresenius Medical Care AG & Co KGaA emerged as a global leader in providing products and services for individuals undergoing dialysis, primarily due to chronic kidney disease (CKD). Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in over 120 countries, serving millions of patients while showcasing a commitment to innovation in renal care. By combining advanced medical technologies with a robust network of outpatient dialysis clinics, Fresenius has positioned itself as a vital player in the healthcare sector. Its commitment to high-quality patient care and effective treatment solutions not only sets it apart but also aligns with the increasing global demand for healthcare services, particularly relevant as the world faces an aging population and rising prevalence of kidney-related conditions. For investors, Fresenius Medical Care represents a compelling opportunity within the expanding healthcare market. The company has demonstrated consistent revenue growth and a resilient business model, generating substantial cash flow, which it reinvests into research and development. This focus on innovation and operational excellence enhances its competitive edge, enabling it to respond swiftly to changes in healthcare regulations and patient needs. With strategic partnerships and integrated care solutions, Fresenius Medical Care is not just navigating the complexities of the healthcare landscape but thriving in it, making it an attractive investment for those looking to enter a sector poised for growth amid increasing global health challenges.
See Also
What is Fresenius Medical Care AG & Co KGaA's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.1B
EUR
Based on the financial report for Jun 30, 2024, Fresenius Medical Care AG & Co KGaA's Cash & Cash Equivalents amounts to 1.1B EUR.
What is Fresenius Medical Care AG & Co KGaA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
9%
Over the last year, the Cash & Cash Equivalents growth was -20%. The average annual Cash & Cash Equivalents growth rates for Fresenius Medical Care AG & Co KGaA have been -8% over the past three years , 3% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
